Search Results

You are looking at 91 - 100 of 179 items for :

  • "acute myeloid leukemia" x
Clear All
Full access

as Vice President of Community and Support for an online virtual world. He holds a bachelor's degree in Computer and Information Sciences from the University of Massachusetts. In November 2010, Mr. Greene was diagnosed with acute myeloid leukemia

Full access

Peter L. Greenberg, Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Virginia Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O’Donnell, Daniel A. Pollyea, Bart Scott, Paul J. Shami, Brady L. Stein, Peter Westervelt, Benton Wheeler, Dorothy A. Shead and Courtney Smith

acute myeloid leukemia (AML) evolution. It should NCCN Guidelines Insights : Myelodysplastic Syndromes, Version 2.2015 Version 2.2015 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this

Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns and Lenora Pluchino

. Additional indications for filgrastim and filgrastim-sndz include treatment for patients with acute myeloid leukemia (AML) receiving induction or consolidation chemotherapy, patients with cancer receiving bone marrow transplant, patients undergoing peripheral

Full access

Gary H. Lyman and Marek S. Poniewierski

developing acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) in patients treated with MGFs. In an analysis of data from the SEER-Medicare linked files, Hershman et al 28 observed a doubling of the risk of subsequent AML or MDS from 0.7% to 1

Full access

Olga Frankfurt and Martin S. Tallman

. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia . Blood 1996 ; 87 : 308 – 313 . 19. Ruiz-Arguelles GJ . Promyelocytic leukemia in Mexican Mestizos . Blood 1997 ; 89 : 348 – 349 . 20

Full access

William Blum

killer immunoglobulin-like receptor (KIR) targeting mAb (anti-KIR) showed activity in early trials for patients with acute myeloid leukemia (AML), myeloma, and lymphoma. Not to be forgotten in a celebration of advances in cancer immunology are those

Full access

& Chief Executive Officer of the National Business Group on Health; John S. Greene, Director of Engineering from Salesforce.com , a survivor of acute myeloid leukemia; Carole Klase, PhD, who survived Merkel cell carcinoma; J. Randall MacDonald, Senior

Full access

Jason Gotlib and Peter L. Greenberg

: 1123 – 1136 . 41 Parker J Mufti G Rasool F . The role of apoptosis, proliferation and the Bcl2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS . Blood 2000 ; 96 : 3932 – 3938 . 42

Full access

Andrew D. Zelenetz and Pamela S. Becker

indications as filgrastim: to treat patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia (FN); patients with acute myeloid leukemia receiving induction or

Full access

Jerald P. Radich

results do not apply to patients on TKIs whose disease has evolved from chronic to accelerated phase, where outcomes are quite poor. As for treatment of patients in blast crisis, in the 1980s and 1990s, various combinations of acute myeloid leukemia (AML